Differential expression of melanoma associated antigens in acral lentiginous melanoma and in nodular melanoma lesions.
暂无分享,去创建一个
[1] J. Johnson,et al. Monoclonal antibody PAL-M1 recognizes the transferrin receptor and is a progression marker in melanocytic lesions. , 1990, The Journal of investigative dermatology.
[2] S. Ferrone,et al. Differential expression of intercellular adhesion molecule 1 in primary and metastatic melanoma lesions. , 1990, Cancer research.
[3] M. Herlyn,et al. Flow cytometric determination of the frequency and heterogeneity of expression of human melanoma-associated antigens. , 1989, Cancer research.
[4] J. Lehmann,et al. MUC18, a marker of tumor progression in human melanoma, shows sequence similarity to the neural cell adhesion molecules of the immunoglobulin superfamily. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[5] M. Maio,et al. Differential role of distinct determinants of intercellular adhesion molecule-1 in immunologic phenomena. , 1989, Journal of immunology.
[6] S. Ferrone,et al. Analysis of the antigenic profile of uveal melanoma lesions with anti-cutaneous melanoma-associated antigen and anti-HLA monoclonal antibodies. , 1989, Cancer research.
[7] D. Ruiter,et al. Differential expression of HLA-DR, DQ, and DP antigens in primary and metastatic melanoma. , 1988, The Journal of investigative dermatology.
[8] C. Perez-Mesa,et al. Plantar lentiginous melanoma. A clinicopathologic study , 1987, Cancer.
[9] L. Miller,et al. Therapy of patients with malignant melanoma using a monoclonal antimelanoma antibody-ricin A chain immunotoxin. , 1987, Cancer research.
[10] D. Elder,et al. Monoclonal antibody-defined correlations in melanoma between levels of GD2 and GD3 antigens and antibody-mediated cytotoxicity. , 1987, Cancer research.
[11] M. Lark,et al. The melanoma proteoglycan: restricted expression on microspikes, a specific microdomain of the cell surface , 1986, The Journal of cell biology.
[12] G. Mariani,et al. Multicenter study of immunoscintigraphy with radiolabeled monoclonal antibodies in patients with melanoma. , 1986, Cancer research.
[13] D. Elder,et al. Proton NMR and fast-atom bombardment mass spectrometry analysis of the melanoma-associated ganglioside 9-O-acetyl-GD3. , 1985, The Journal of biological chemistry.
[14] V. Hearing,et al. Anti-T4-tyrosinase monoclonal antibodies--specific markers for pigmented melanocytes. , 1985, The Journal of investigative dermatology.
[15] M. Melamed,et al. Surface antigens of melanomas and melanocytes defined by mouse monoclonal antibodies: specificity analysis and comparison of antigen expression in cultured cells and tissues. , 1985, Cancer research.
[16] D. Ruiter,et al. Monoclonal antibodies selected to discriminate between malignant melanomas and nevocellular nevi. , 1985, The Journal of investigative dermatology.
[17] N. Cheung,et al. Monoclonal antibodies to a glycolipid antigen on human neuroblastoma cells. , 1985, Cancer research.
[18] M. Melamed,et al. Mouse monoclonal IgG3 antibody detecting GD3 ganglioside: a phase I trial in patients with malignant melanoma. , 1985, Proceedings of the National Academy of Sciences of the United States of America.
[19] R. Reisfeld,et al. Biosynthetic studies of proteoglycans in human melanoma cells with a monoclonal antibody to a core glycoprotein of chondroitin sulfate proteoglycans. , 1984, The Journal of biological chemistry.
[20] S. Larson,et al. Localization of 131I-labeled p97-specific Fab fragments in human melanoma as a basis for radiotherapy. , 1983, The Journal of clinical investigation.
[21] J. Cairncross,et al. Surface antigens of melanocytes and melanomas. Markers of melanocyte differentiation and melanoma subsets , 1982, The Journal of experimental medicine.
[22] S. Ferrone,et al. HETEROGENEOUS DISTRIBUTION OF THE DETERMINANTS DEFINED BY MONOCLONAL ANTIBODIES ON HLA‐A AND B ANTIGENS BEARING MOLECULES , 1982, Transplantation.
[23] W. Coleman,et al. Acral Lentiginous Melanoma: A Clinicopathologic Entity , 1982, Annals of surgery.
[24] S. Ferrone,et al. A 94,000-dalton glycoprotein expressed by human melanoma and carcinoma cells. , 1982, Journal of the National Cancer Institute.
[25] S. Ferrone,et al. Distribution and molecular characterization of a cell‐surface and a cytoplasmic antigen detectable in human melanoma cells with monoclonal antibodies , 1981, International journal of cancer.
[26] L. Old,et al. Cell surface antigens of human malignant melanoma: definition of six antigenic systems with mouse monoclonal antibodies. , 1980, Proceedings of the National Academy of Sciences of the United States of America.
[27] J. Brown,et al. Protein antigens of normal and malignant human cells identified by immunoprecipitation with monoclonal antibodies. , 1980, The Journal of biological chemistry.
[28] C. Schmoeckel. Prognostic Index in Malignant Melanoma , 1980 .
[29] M. Pike,et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. , 1977, British Journal of Cancer.
[30] K. Hellström,et al. Human tumor antigens. , 1971, The New England journal of medicine.
[31] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .
[32] J. Johnson,et al. De novo expression of intercellular-adhesion molecule 1 in melanoma correlates with increased risk of metastasis. , 1989, Proceedings of the National Academy of Sciences of the United States of America.
[33] D. Ruiter,et al. Immunodiagnostic and immunotherapeutic applications of anti human melanoma associated antigen monoclonal antibodies. , 1989, Carcinogenesis; a comprehensive survey.
[34] M. Herlyn,et al. Melanoma antigens: immunological and biological characterization and clinical significance. , 1988, Annual review of immunology.
[35] J. Coligan,et al. HLA‐DC antigens can serve as recognition elements for human cytotoxic T lymphocytes , 1984, European journal of immunology.
[36] F. Bach,et al. Detection of a novel human class II HLA antigen , 1983, Nature.